We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Peak Expiratory Flow Rate for Emergency Department Management of Acute Asthma Exacerbation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03420651
Recruitment Status : Recruiting
First Posted : February 2, 2018
Last Update Posted : February 5, 2018
Sponsor:
Information provided by (Responsible Party):
Brian Driver, Minneapolis Medical Research Foundation

Brief Summary:
Patients presenting to the emergency department with acute asthma exacerbation will be assigned to peak-expiratory flow rate (PEFR) guided management and non-PEFR guided management.

Condition or disease Intervention/treatment
Asthma Other: Peak Expiratory Flow Rate (PEFR) Other: Standard Clinical Judgement

Detailed Description:

It is common practice to use peak-expiratory flow rate (PEFR) as an indicator of severity in patients that present with acute asthma exacerbation. There is, however, little data supporting this practice.

A recent Canadian 20 site prospective observational cohort study of 805 ED patients with acute asthma exacerbation concluded PEFR was not useful in predicting need for hospitalization or relapse following discharge.

As this was a cohort observational study, the conclusions that can be drawn are limited by the lack of randomization and control; it is necessary to conduct a randomized controlled trial to quantify how much time is expended caring for these patients, and gather safety data.

This is important because no studies have quantified differences in resource utilization based on PEFR-guided management compared to non-PEFR-guided management. It is possible physicians following PEFR-guided management use comparatively more resources, such as nebulizer treatments and hospitalization, in order to treat low PEFR values in patients they would have otherwise discharged based on clinical judgement alone. If outcomes are not affected by non-PEFR-guided management, it may reduce resource utilization to avoid using PEFR-guided management.

The investigators seek to determine if PEFR-based management and non-PEFR-based management perform similarly in guiding ED management of acute asthma exacerbations. Specifically, they seek to determine if the proportion of patients with no or mild asthma symptoms at 150 minutes after enrollment arrival is similar in the two groups.

At 150 minutes, it is expected that approximately 80% of patients will have no or mild asthma symptoms in both groups. When comparing the proportion of patients between the two groups, a confidence interval less than 20% wide (10% on either side of the point estimate) is desired. Therefore, goal enrollment is 110 patients per group.

This study will only include patients who are discharged from the ED. Patients who are enrolled and then eventually admitted to the hospital will be tabulated but excluded from the analysis.

Statistical analysis will compare the difference in the proportion of patients who achieve the primary outcome between groups, with the associated 95% confidence interval. Secondary outcomes will be presented descriptively; depending on the final distribution of the data, the investigators will present the means or medians of the data with the associated difference in mean/median with the associated 95% confidence intervals


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Masking Description: When patients are randomized to the non-peak flow guided therapy, physicians are blinded to the peak flow values
Primary Purpose: Treatment
Official Title: Peak Expiratory Flow Rate (PEFR) for Emergency Department Management of Acute Asthma
Actual Study Start Date : January 19, 2018
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: PEFR Guided Management
Peak Expiratory Flow Rate (PEFR) Patients in this group will perform PEFR testing every 30 minutes and this data along with the National Asthma Prevention and Education Program guidelines will be considered by primary ED medical providers in the management of this group.
Other: Peak Expiratory Flow Rate (PEFR)
PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
Experimental: Non-PEFR Guided Management
Standard Clinical Judgement Patients in this group will receive management based on primary medical provider's clinical judgement.
Other: Standard Clinical Judgement
Providers will use physical exam and standard clinical judgement to guide management.



Primary Outcome Measures :
  1. Adequate control of asthma symptoms within 150 minutes [ Time Frame: 150 minutes ]
    Proportion of patients reporting no or mild asthma symptoms at 150 minutes after enrollment


Secondary Outcome Measures :
  1. Hospitalization during index encounter [ Time Frame: 12 hours ]
    Rate of hospitalization in both groups directly from initial ED encounter

  2. ED Length of Stay [ Time Frame: 12 hours ]
    Time elapsed from when the patient is roomed until the time the MD places discharge order, by review of the Electronic Medical record by a blinded abstractor.

  3. Number of nebulized treatments with short-acting beta antagonists (SABA) [ Time Frame: 12 hours ]
    This is defined as the number of nebulized treatments received in the emergency department during the encounter, by review of the Electronic Medical record by a blinded abstractor.

  4. Relapse following discharge within 72 hours [ Time Frame: 72 hours ]
    Each patient will be assessed via chart review and telephone follow up to see if they visited an ED or urgent care for asthma symptoms during the 72 hour time frame. Rates of relapse will be compared between the two treatment arms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presumed diagnosis of asthma, requiring at least 2 nebulized albuterol treatments
  • Presenting with acute asthma exacerbation defined as acute or subacute episodes of progressively worsening shortness of breath, cough, wheezing, and chest tightness, or some combination of these symptoms
  • Start of enrollment process must occur within 15 minutes of being roomed in the ED
  • Working phone number and willingness to be contacted at least 72 hours following encounter

Exclusion Criteria:

  • Prisoner or in custody
  • Pregnant
  • Known diagnosis of COPD
  • Co-morbid medical conditions that patient is seeking treatment for concurrently
  • Non-English speaking
  • Unable to provide informed consent
  • In the resuscitation bay or on non-invasive positive pressure ventilation (NPPV)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03420651


Contacts
Contact: Audrey Hendrickson 612-873-7448 audrey.hendrickson@hcmed.org

Locations
United States, Minnesota
Hennepin County Medical Center Recruiting
Minneapolis, Minnesota, United States, 55415
Contact: Audrey Hendrickson    612-873-7448    audrey.hendrickson@hcmed.org   
Hennepin County Medical Center Recruiting
Minneapolis, Minnesota, United States, 55415
Contact: Audrey Hendrickson    612-873-9528    audreyh@umn.edu   
Sponsors and Collaborators
Minneapolis Medical Research Foundation

Responsible Party: Brian Driver, Director of Clinical Research, Minneapolis Medical Research Foundation
ClinicalTrials.gov Identifier: NCT03420651     History of Changes
Other Study ID Numbers: 17-4459
First Posted: February 2, 2018    Key Record Dates
Last Update Posted: February 5, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Asthma
Emergencies
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Disease Attributes
Pathologic Processes